Latest Coles News

MyEco Group has reported a record quarter for its MyEcoBag® products, driven by strong Australian retail growth and poised to benefit from upcoming NSW organic waste regulations.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

NeuroScientific Biopharmaceuticals reports encouraging clinical responses in fistulising Crohn’s disease patients treated under Australia’s Special Access Scheme, setting the stage for pivotal Phase 2 trials later this year.

Elanor Commercial Property Fund has reaffirmed its FY26 distribution guidance of 6.5 cents per security, buoyed by strong leasing activity and a modest uplift in portfolio valuations. However, potential management changes could cloud future payouts.

MyEco Group reveals a strategic pivot towards expanding its MyEco branded products, achieving a 9% sales increase in FY25, and implementing a $2.5 million cost-saving operational restructure aimed at EBITDA breakeven in FY26.

SHAPE Australia has agreed to acquire Arden Group, expanding its footprint in retail fitout and facilities maintenance with an earnings accretive deal.

TasFoods reports a 13.2% revenue decline in Q3 2025 driven by oversupply and discounting in the Tasmanian poultry market, while advancing a $2 million sale of Pyengana Dairy and reducing debt through property sales.

Pure Foods Tasmania reported a $1 million operating cash outflow in the September quarter due to restructuring and timing factors but anticipates positive cash flow and growth driven by new Coles product launches and operational efficiencies.

Entertainment Rewards Ltd reported a 2.2% revenue increase in Q1 FY26, driven by strong membership growth and Card Linked Offers, while securing an additional $3 million loan to support its strategic initiatives.

Nuchev Limited reported a robust 30% increase in group revenue to $6.5 million in Q1 FY26, driven by strong sales across ANZ, China, and a new foothold in Vietnam. The company’s strategic acquisitions and product launches underpin its expanding market presence and diversification.

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

Coles Group reported a solid 3.9% rise in first quarter sales for FY26, driven by strong supermarket growth and digital expansion, while liquor sales faced ongoing market challenges.